Interesting Dosages of Semaglutide between Three Brands
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus.Semaglutide is a synthetic derivative based on the naturally occurring GLP-1peptide, which is known for its ability to reduce blood sugar levels and enhance insulin secretion. Recent research suggests that Semaglutide may also have positive effects on heart, liver, and lung function. And it could potentially slow down or prevent the progression of Alzheimer’s disease.
2. How does Semaglutide work?
Semaglutide works as a GLP-1 agonist, meaning it mimics the effects of a hormone called glucagon-like peptide-1 (GLP-1) in the body. GLP-1 is naturally released by the intestines in response to food intake and plays a crucial role in regulating blood sugar levels and appetite.
When semaglutide is injected, it binds to and activates GLP-1 receptors on various cells in the body, including pancreatic cells. This activation leads to several beneficial effects. First, semaglutide increases insulin release from the pancreas, which helps lower blood sugar levels by facilitating the uptake of glucose into cells for energy. Increased insulin also helps to reduce the production of glucose by the liver. Second, semaglutide suppresses the release of glucagon, a hormone that raises blood sugar levels. By reducing glucagon levels, semaglutide further contributes to the overall control of blood sugar.
3. Benefits of Semaglutide
Improved blood sugar control. Semaglutide, as a GLP-1 receptor agonist, helps regulate blood sugar levels in individuals with type 2 diabetes. It stimulates insulin release from the pancreas, which leads to better glucose utilization by the body’s cells. By reducing glucagon secretion and slowing down gastric emptying, semaglutide helps lower blood sugar levels and maintain better glycemic control.
Weight loss. Semaglutide has been found to promote weight loss when used for weight management in individuals with obesity or excess weight. By suppressing appetite and inducing a feeling of fullness, it can help reduce calorie intake and contribute to sustainable weight loss when combined with a reduced-calorie diet and exercise.
Cardiovascular risk reduction. In individuals with type 2 diabetes and established cardiovascular disease, semaglutide (specifically Ozempic) has been shown to reduce the risk of major cardiovascular events like heart attack or stroke. This benefit can provide additional protection to individuals with both diabetes and cardiovascular conditions.
Potential benefits in cognition. Semaglutide has shown potential benefits in improving cognitive function, particularly in individuals with mildl cognitive impairment or mild dementia caused by Alzheimer’s disease. It has been found to protect against amyloid-ß plaques, which are associated with cognitive decline in Alzheimer’s disease. Preclinical studies and ongoing clinical trials are evaluating semaglutide’s impact onl cognitive function. Results from these trials will provide more information about semaglutide’s effectiveness in improving cognitive abilities in Alzheimer’s disease.
4. Side effects of Semaglutide
Side effects from semaglutide injection might occur. If any of these symptoms are severe or do not go away, let your doctor know right once:
5. Dosages of Semaglutide (For Type 2 Diabetes Mellitus)
(1) Ozempic (semaglutide injection):
Initial Dose: 0.25 mg subcutaneously once weekly for 4 weeks.
Maintenance Dose: After the initial 4 weeks, increase the dose to 0.5 mg subcutaneously once weekly.
Further Dose Adjustment: If glycemic control is not achieved after at least 4 weeks on the 0.5 mg dose, the dose can be increased to 1 mg once weekly.
Maximum Dose: If needed, the dose can be further increased to 2 mg once weekly, but it should not exceed 2 mg per week.
(2) Rybelsus (oral semaglutide tablets):
Initial Dose: 3 mg orally once daily for 30 days (intended for treatment initiation, not for glycemic control).
Maintenance Dose: After 30 days on the 3 mg dose, increase the dose to 7 mg orally once daily.
Further Dose Adjustment: If additional glycemic control is needed, the dose can be increased to 14 mg orally once daily.
Note: Taking two 7 mg tablets to achieve the 14 mg dose is not recommended.
(3) Switching between Ozempic and Rybelsus:
Switching from Rybelsus to Ozempic: Start with 0.5 mg subcutaneously once weekly on the day after the last Rybelsus dose.
Switching from Ozempic to Rybelsus: Start with 7 mg or 14 mg orally once daily, up to 7 days after the last Ozempic injection. There is no equivalent oral dose for the 1 mg Ozempic dose.